---
title: "Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291139753.md"
description: "The FDA has implemented a rolling review process to expedite evaluations of New Drug Applications (NDAs). This allows the FDA to review completed modules of the NDA before the entire application is submitted. The aim is to streamline the review process and accelerate the approval timeline, benefitting both the FDA and the applicants. This process is particularly beneficial in cases where time is crucial, allowing for earlier feedback and potentially speeding up the overall approval process."
datetime: "2026-06-29T11:31:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291139753.md)
  - [en](https://longbridge.com/en/news/291139753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291139753.md)
generator: "portal-rs"
---

# Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

The FDA has implemented a rolling review process to expedite evaluations of New Drug Applications (NDAs). This allows the FDA to review completed modules of the NDA before the entire application is submitted. The aim is to streamline the review process and accelerate the approval timeline, benefitting both the FDA and the applicants. This process is particularly beneficial in cases where time is crucial, allowing for earlier feedback and potentially speeding up the overall approval process.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [Primecap Management Co. CA Makes New Investment in Palvella Therapeutics, Inc. $PVLA](https://longbridge.com/en/news/297156499.md)
- [Bonesupport says FDA extends deadline for Cerament V additional data package to October](https://longbridge.com/en/news/297131100.md)
- [Egetis says FDA sets Sept. 28 PDUFA date for Emcitate in MCT8 deficiency](https://longbridge.com/en/news/297005603.md)
- [Capricor says FDA sets Nov. 22 PDUFA date for deramiocel in Duchenne muscular dystrophy](https://longbridge.com/en/news/296796555.md)
- [HHS said to be eyeing two new FDA deputy commissioners for technology and drugs](https://longbridge.com/en/news/296945299.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**